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Abstract 
Multiple Myeloma (MM) is a cancer of plasma 
cells resulting from the abnormal proliferation of 
malignant plasma cells within the bone marrow 
(BM) microenvironment. MM accounts for 1.3% of 
all malignancies and 12% of hematologic cancers, 
and is the second most commonly diagnosed blood 
cancer after non-Hodgkin lymphoma. The hallmark 
characteristics of MM include: high levels of intact 
monoclonal immunoglobulin or its fragment (free 
light chain) in serum or urine, and excess 
monotypic plasma cells in the bone marrow in 
conjunction with evidence of end organ damage 
related to MM: (1) hypercalcemia, (2) renal failure, 
(3) anemia, and (4) osteolytic bone lesions or severe 
osteopenia, known as CRAB criteria. Even though 
novel agents targeting MM cells in the context of 
the BM microenvironment such as proteasome 
inhibitors, immunomodulatory drugs (IMiDs), and 
monoclonal antibodies have significantly prolonged 
survival in MM patients, the disease remains 
incurable. A deeper understanding of the molecular 
mechanisms of MM growth, survival, and 
resistance to therapy, such as genomic instability, 
clonal heterogeneity and evolution, as well as MM-
BM microenvironmental host immune and other 
factors, will provide the framework for 
development of novel therapies to further improve  
patient outcome. 
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Identity 
Other names 
Plasma cell myeloma, Myelomatosis, Kahler's 
disease 
Note 
This paper is an update of Multiple myeloma in 
2004. 
Clinics and pathology 
Disease 
MM is a plasma cell cancer which is preceded by 
an asymptomatic, premalignant condition called 
monoclonal gammopathy of undetermined 
significance (MGUS) which then progresses to MM 
or related malignancies with a rate of about 1% per 
year (Zingone and Kuehl 2011). 
Phenotype/cell stem origin 
Antigen-selected, post-germinal center, terminally 
differentiated plasma cell (Anderson and Carrasco 
2011) 
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Top: Normal Bone Marrow; Bottom: Multiple Myeloma Bone Marrow (note: ≥ 10% clonal bone marrow plasma cells). Image 
taken from: http://www.thrombocyte.com/causes-of-multiple-myeloma-cancer/ 
 
Etiology 
Etiology not known. No confirmed predisposing 
factors.  
Possible (unconfirmed and controversial) risk 
factors include (Sundar Jagannath et al 2016):  
 Environmental factors such as radiation exposure, 
occupational exposure (agricultural, chemical, 
metallurgical, rubber plant, pulp, wood, paper), and 
chemical exposure (formaldehyde, epichlorohydrin, 
Agent orange, hair dyes, paint sprays, asbestos) 
 Viral infection: Herpesvirus 8 infection noted in 
some patients with MM 
 Genetic predisposition 
The transformation of normal plasma cells into 
myeloma cells is thought to result from one of two 
primary genetic events: either (1) hyperdiploidy or 
(2) aberrant class switch recombination (CSR), 
likely occurring in the germinal center, leading to 
MGUS. Secondary cytogenetic abnormalities result 
in the progression of MGUS to SMM, MM, and 
plasma cell leukemia (PCL) (see below: 
Cytogenetics). MM cells are dependent upon the 
BM microenvironment for growth, survival, and 
drug resistance, due both to tumor cell adhesion to 
BM accessory cells and release of growth factors 
and cytokines including (1) interleukin-6 ( IL6), (2) 
vascular endothelial growth factor ( VEGFA), (3) 
insulin-like growth factor 1 ( IGF1), (4) members 
of the superfamily of tumor necrosis factor, (5) 
transforming growth factor beta1 (TGFB1), and (6) 
interleukin-10 ( IL10) (Palumbo and Anderson 
2011). Coupled with various genetic changes, these 
abnormal microenvironmental interactions between 
MM cells and BM cells contribute to aberrant 
angiogenesis and MM disease progression 
(Palumbo and Anderson 2011). 
Epidemiology 
See table below. 
Clinics 
The most common presenting symptoms of MM are 
fatigue and bone or back pain. Multiple myeloma 
cells typically grow within the BM of the spine, 
skull, ribs, sternum, pelvis, humeri, and femora, 
causing pain, osteopenia, and frequently 
pathological fractures (Palumbo and Anderson 
2011).  
Myeloma cells typically secrete an excess of a 
monoclonal immunoglobulin or its fragments (free 
light chain), which can then be detected in the 
patient's serum and/or urine via protein 
electrophoresis and serum free light chain (sFLC) 
testing, respectively. Immunofixation shows the 
myeloma (M) protein to be monoclonal in nature 
and identifies heavy (IgG/IgA/IgM/IgD, in order of 
frequency) and light chain ( κ/λ) specific isotype.  
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Rarely, MM may be non-secretory and neither a 
monoclonal Ig nor an excess sFLC can be 
identified. The diagnosis of MM is made based on 
the percentage of bone marrow involvement by 
clonal MM cells, size of M protein spike, and 
presence/absence of end-organ damage (CRAB) or 
myeloma-defining biomarkers (Rajkumar, 
Dimopoulos et al. 2014). 
CRAB criteria:  
Hypercalemia -> (C)  
Up to 20% of newly diagnosed patients have 
hypercalcemia due to bone destruction. 
Hypercalcemia is associated with high tumor 
burden and requires prompt treatment with 
aggressive hydration and loop diuretic therapy, 
bisphosphonates, calcitonin, and anti-myeloma 
therapy for disease control. 
Renal Failure -> (R)  
Renal dysfunction (anuria or oliguria) resulting 
from direct tubular damage by free light chain 
tubular or glomerular deposition, hypercalcemia, 
dehydration, and nephrotoxic medications (NSAIDs 
for pain control, IV radiographic contrast, 
bisphosphonates) is present in 20 to 40% of newly 
diagnosed patients.  
Light-chain cast nephropathy is the most common 
cause of renal failure in MM. Other causes include  
amyloidosis and light-chain deposition disease. 
Anemia-> (A)  
At diagnosis, symptomatic normocytic, 
normochromic anemia (typically secondary to 
myelophthisis and hyporegenerative BM) is present 
in approximately 73% of patients. Mean 
corpuscular volume (MCV) may be macrocytic; an 
artifact related to rouleaux formation. 
Bone Disease -> (B)  
Up to 58% of patients report bone pain (especially 
from compression fractures of vertebrae or ribs), 
and up to 80% of newly diagnosed patients have 
bony lesions.  
The characteristic "punched-out" osteolytic lesions 
result from lytic bone destruction that is uncoupled 
from reactive bone formation. MM cells increase 
the activity of osteoclasts by upregulating osteoclast 
inducers (i.e. TNFSF11 (RANKL, TRANCE), 
CCL3 and CCL4 (MIP-1 alpha /beta), CXCL12 
(SDF-1 alpha), IL1B (IL-1 beta), TNF (TNF-
alpha), IL6,) and downregulating TNFRSF11B 
(OPG, decoy receptor for RANKL). 
Simultaneously, MM cells suppress osteoblast 
differentiation and function (by producing DKK1) 
resulting in an imbalance favouring bone resorption 
(osteoclast activation) over bone formation 
(osteoblast suppression) (Sezer 2009). 
 
Revised International Staging System (R-ISS) (Palumbo, Avet-Loiseau et al. 2015)*Standard-risk: No high-risk 
chromosomal  abnormality. High-risk: Presence of del(17p) and/or translocation t(4;14)  and/or translocation t(14;16) 
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International Myeloma Working Group (IMWG) diagnostic criteria (Rajkumar, Dimopoulos et al. 2014) 
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M-protein Left: Serum protein electrophoresis showing characteristic "M-protein" spike. Image taken from: 
http://bestpractice.bmj.com/best-practice/images/bp/en-gb/179-5-iline_default.gif and  
http://www.aafp.org/afp/1999/0401/p1885.html; Right: Urine protein electrophoresis showing gamma-globulin peak 
corresponding to Bence-Jones proteinuria. Image taken from: https://ahdc.vet.cornell.edu/sects/clinpath/test/immun/electro.cfm 
 
Pathology 
MM is characterized by the presence of ≥10% 
malignant plasma cells in the bone marrow. MM 
can be divided into (1/>= secretory MM, (2) 
oligosecretory MM (aka light chain MM), and (3) 
non-secretory MM based on whether M-protein is 
secreted and detectable (Lonial and Kaufman 
2013). Non-secretory MM accounts for <5% of 
cases and can be further divided into producer (i.e. 
patients who have detectable M-protein within MM 
cells but do not secrete M-protein) and non-
producer MM (patients who do not have detectable 
M-protein even within MM cells) (Lonial and 
Kaufman 2013). The presence of Bence-Jones 
protein (BJP) in the urine indicates the excessive 
production of monoclonal light-chain proteins that 
exceeds the re-absorptive ability of the proximal 
tubules. These filtered light-chains are, in their 
various forms (free, tubular casts, amyloid), 
nephrotoxic and are responsible for the most 
common cause of renal failure in patients with MM. 
Another hallmark feature of MM is the presence of 
osteolytic bone lesions that results from an 
imbalance favoring bone resorption over bone 
formation due to increased osteoclast activity and 
reduced osteoblast differentiation and function, 
secondary to secreted factors from MM cells (Sezer 
2009). Associated with bone destruction are 
complications such as bone pain, pathological 
fractures, and hypercalcemia. Anemia is another 
frequent finding in patients with MM that results 
from multiple mechanisms including anemia of 
chronic disease, EPO deficiency (secondary to renal 
impairment), myelosuppression from 
chemotherapy, and bone marrow infiltration by 
plasma cells. 
 
 Osteolytic bone lesions (a-d) X-rays showing characteristic osteolytic bone lesions typical sites such as the (a) skull, (b) tibia, 
(c) femur, and (d) pelvis. Image taken from: http://orthoinfo.aaos.org/topic.cfm?topic=A00086 ; (e) Sagittal CT showing multiple 
osteolytic bone lesions of the vertebral column. Image taken from: https://radiopaedia.org/cases/multiple-myeloma-skeletal-
survey 
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MM kidney disease Left: Normal kidney biopsy; Right: Monoclonal protein-containing casts surrounded by histiocytes and giant 
cells. Note the presence of acute tubular injury and interstitial nephritis which are commonly seen in MM kidney disease. Images 
taken from: https://ajkdblog.org/2012/06/14/test-your-knowledge-myeloma-and-the-kidney/#prettyPhoto (courtesy of Dr. Tibor 
Nadasdy) 
 
Natural History of MM Monoclonal Gammopathy of Undetermined Significance (MGUS; premalignant; asymptomatic) -> 
Smoldering Multiple Myeloma (SMM; pre-malignant; asymptomatic) -> Multiple Myeloma (MM; malignant; symptomatic) -> 
Plasma cell Leukemia (PCL), extramedullary disease. MM remains incurable in the long-term as most patients inevitably, yet 
unpredictably, develop refractory relapse disease (i.e. disease that fails to respond to induction or salvage therapy, or progresses 
within 60 days of last therapy). Images taken from: Kyle et al, NEJM, Volume 356:2582-2590 (Kyle, Remstein et al. 2007)  and 
Roman Hajek, Intech open, DOI: 10.5772/55366 (Hajek 2013) 
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Treatment 
See tables 
(NCCN guidelines version 3.2017) and IMWG 
RESPONSE CRITERIA (Kumar, Paiva et al. 2016)  
Prognosis 
Varies greatly depending on:  
-Stage of disease (see above: ISS) 
-Cytogenetics (see below: cytogenetics) 
-LDH levels (high levels associated with 
extramedullary disease, plasma cell leukemia, 
plasmablastic disease, plasma cell hypoploidy, drug 
resistance, and poor outcomes) 
-Plasma cell labeling index 
-C-reactive protein (high levels associated with 
poor outcomes) 
-Plasmablastic histology 
-Extramedullary disease 
-Age 
Type of treatment available 
- Conventional therapy: OS ~3 years; EFS <2 years 
- High-dose chemotherapy and stem-cell 
transplantation:  5-year OS >50% 
In general, poor prognosticators include:  
-Large tumor burden 
- Hypercalcemia 
- High LDH 
- Bence-Jones proteinuria  
- Renal impairment 
- IgA subtype 
- Extramedullary disease at presentation 
Genetics 
See figure below. 
Cytogenetics 
Cytogenetics morphological 
See figures below. 
Genes involved and 
proteins 
FGFR3 (Fibroblast Growth Factor 
Receptor 3) 
Location 
4p16.3 
Note 
Involved in t(4;14)(p16;q32) 
Both FGFR3 and WHSC1 (MMSET) are 
implicated in the translocation with IGH 
Incidence: 6-12% 
NSD2 (MMSET) 
Location 
4p16.3 
Note 
Involved in t(4;14)(p16;q32) 
CCND1 (B-cell leukemia/lymphoma 1) 
Location 
11q13.3 
Note 
Involved in t(11;14)(q13;q32)  
Incidence: 15-20% 
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Genetics 
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Primary Cytogenetic Abnormalities (Normal plasma cell --> MGUS/SMM). Ref : Rajan and Rajkumar (2015)  
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Secondary Cytogenetic Abnormalities (MGUS/SMM --> MM --> RR MM, PCL) Ref : Morgan, Walker et al. (2012). 
 
 
CCND3 (cyclin D3) 
Location 
6p21.1 
Note 
Involved in t(6;14)(p21;q32)  
Incidence: 5% 
MAF (v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
(avian)) 
Location 
16q23.2 
Note 
Involved in t(14;16)(q32;q23) 
Incidence: 4-10% 
IRF4 (interferon regulatory factor 4) 
Location 
6p25.3 
Note 
Involved in t(6;14)(p25;q32) 
Incidence: 5% 
MYC v-myc myelocytomatosis viral 
oncogene homolog (avian) 
Location 
8q24.21 
Note 
Involved in t(8;14)(q24;q32) 
Incidence: <10% 
MAFB (v-maf avian 
musculoaponeurotic fibrosarcoma 
oncogene homolog B) 
Location 
20q12 
Note 
Involved in t(14;20)(q32;q11)  
Incidence: 1 - 5% 
BCL9 (B-cell CLL/lymphoma 9) 
Location 
1q21.2 
Note 
Incidence: Frequent 
Both BCL9, IL6R, and MCL1 can be deleted 
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IL6R (interleukin 6 receptor) 
Location 
1q21.3 
Note 
Incidence: Frequent 
MCL1 (MCL1, BCL2 family apoptosis 
regulator) 
Location 
1q21.2 
Note 
Incidence: Frequent 
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